Optimising the care and quality of life of people with cystic fibrosis: the influence of cystic fibrosis transmembrane conductance regulator modulators. (2nd November 2021)

• Record Type: Journal Article
• Authors: Shaw, Nicola; Collins, Sarah; Smith, Thomas; McCulloch, Anna; Ketchell, Ian; Edwards, Viv; Blaikie, Lesley; Daniels, Tracey
• Is Part Of: British journal of hospital medicine. Volume 82:Number 11(2021)
• Page Start: 1
• Page End: 6
• Publication Date: 2021-11-02
• Subjects: Cystic fibrosis -- Cystic fibrosis transmembrane conductance regulator (CFTR) modulators -- Physiotherapy -- Quality of life; Medicine -- Periodicals; Hospital care -- Periodicals; 610.5
• DOI: 10.12968/hmed.2021.0530
• Languages: English
• ISSNs: 1750-8460

Abstract

Abstract : Cystic fibrosis is a life-limiting, inherited, multi-organ disease which affects many systems of the body. Until recently, treatments were only able to ameliorate symptoms, but the introduction of precision medications which modulate the underlying defect in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene has changed this. Notably improvements in nutrition and lung function, reduced use of antibiotics and reduced occupation rates for hospital beds have been seen. This article summarises the discussion of a group of healthcare professionals from different specialties and an expert patient, representing their personal views and experience of treating patients who are using CFTR modulators. The discussion was sponsored by an unrestricted grant from Chiesi Limited (Manchester, UK).